

Name of project	Immuno-oncology pathway configuration project (IPC project): A Joint Working Project between Velindre Cancer Centre, Velindre NHS Trust (VCC) & Bristol-Myers Squibb Pharmaceuticals Ltd (BMS)
Project Overview	<p>Velindre Cancer Centre, Velindre NHS Trust has identified a need to improve the quality and productivity of oncology services to patients. The overall objective is to ensure that patients are cared for in the most appropriate environment. This is an environment where quality is maximised, where processes are efficient and variation is minimal, where patients feel safe and well cared for and patient experience is optimised.</p> <p>Velindre Cancer Centre, Velindre NHS Trust and BMS wish to work together to develop, plan and prepare a project for approval for implementation.</p>
Project objectives	<ul style="list-style-type: none"> <li>• To design and plan a high quality and patient focused service configuration that can accommodate the expected increase in patient numbers and demand on services, resulting from increasing use of I-O treatments, both in the short term and a longer time frame (2021)</li> <li>• To ensure prudent use of healthcare resources.</li> </ul>
Patient benefits	<ul style="list-style-type: none"> <li>• A service that meets the patient/service user requirements and needs (for example: care closer to home, domiciliary visits, reduced waiting times, more responsive service, etc)</li> <li>• Improved patient experience through provision of a streamlined, efficient service</li> </ul>
Stakeholders	<ul style="list-style-type: none"> <li>• Velindre Cancer Centre, Velindre NHS Trust</li> <li>• Bristol-Myers Squibb Pharmaceuticals Ltd</li> </ul>
Timelines	The project will start from date on which the disclosure statement goes live on the BMS website and finish twelve months after this date.

Job bag number: ONCUK1900113-01

Date of prep: Jan 2019